Jack Zhou, MD
Internal Medicine · Honolulu, HINPI 1265402168
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 586 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 586 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- AbbVie$1K
- Amgen$1K
- AstraZeneca$1K
- GSK$995
- Boehringer Ingelheim$719
- plus $4K from 19 others
What the payments were for
- Food & beverage$11,13099%
- Education$631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 127 | $1,599 |
| AbbVie(2 entities) | 57 | $1,488 |
| Amgen | 46 | $1,140 |
| AstraZeneca | 45 | $1,034 |
| GSK | 76 | $995 |
| Boehringer Ingelheim | 29 | $719 |
| Pfizer | 35 | $657 |
| Novo Nordisk | 29 | $652 |
| Lilly USA, LLC | 29 | $625 |
| Amarin Pharma, Inc. | 28 | $570 |
| Bayer | 18 | $405 |
| Kowa Pharmaceuticals America, Inc. | 13 | $249 |
| Johnson & Johnson | 12 | $247 |
| Merck | 9 | $182 |
| Astellas Pharma US Inc | 8 | $140 |
| Novartis | 7 | $134 |
| Ironwood Pharmaceuticals, Inc | 4 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $54 |
| E.r. Squibb & Sons, L.L.C. | 2 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Insulet Corporation | 1 | $25 |
| Exact Sciences | 1 | $25 |
| Radius Health, Inc. | 1 | $23 |
| Smith+Nephew | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,193 in reported general payments places this provider in the 90th percentile of 655 internal medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 314 | $302,169 |
| EliquisApixaban | 232 | $232,084 |
| JanuviaSitagliptin Phosphate | 171 | $184,597 |
| ProliaDenosumab | 99 | $176,078 |
| OzempicSemaglutide | 167 | $174,937 |
| LinzessLinaclotide | 244 | $162,985 |
| VemlidyTenofovir Alafenamide | 107 | $162,619 |
| FarxigaDapagliflozin Propanediol | 107 | $121,031 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 136 | $97,844 |
| JanumetSitagliptin Phos/Metformin Hcl | 109 | $97,819 |
| TrulicityDulaglutide | 50 | $60,577 |
| CreonLipase/Protease/Amylase | 32 | $41,703 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 59 | $33,236 |
| RestasisCyclosporine | 44 | $30,391 |
| VascepaIcosapent Ethyl | 68 | $29,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet, Janumet Xr | $182 | $304,590308 claims |
| Boehringer IngelheimJardiance | $719 | $302,169314 claims |
| AbbVieLinzess, Creon, Restasis, Alphagan P | $1,488 | $240,656333 claims |
| PfizerEliquis | $657 | $232,084232 claims |
| AmgenProlia | $1,140 | $176,07899 claims |
| Novo NordiskOzempic | $652 | $174,937167 claims |
| GileadVemlidy | $1,599 | $162,619107 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $1,034 | $143,557163 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $995 | $131,081195 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $625 | $76,96465 claims |
| Astellas Pharma US IncMyrbetriq | $140 | $19,06323 claims |
| NovartisEntresto | $134 | $15,32521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 655 internal medicine providers in Hawaii.
Other internal medicine in Honolulu
- Keith WooHonolulu$106K
- Ronald PerryHonolulu$102K
- Laurie TomHonolulu$95K
- Yusuke MiyataniHonolulu$80K
- Joshua TanHonolulu$76K
- Jose de LeonHonolulu$52K
- Peter DeeHonolulu$49K
- James LumengHonolulu$45K
- Charles ZerezHonolulu$44K
- Anthony HernandezHonolulu$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.